Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 8, 2010, Pages 1394-1400

  Rhee, Eugene P ^a   Laliberte, Karen A ^a   Niles, John L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; AVASCULAR NECROSIS; CLINICAL ARTICLE; COLITIS; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE EXACERBATION; FEMALE; FEVER; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MACROCYTIC ANEMIA; MAINTENANCE THERAPY; MALE; NEUTROPENIA; PANCYTOPENIA; REMISSION; RIGOR; SIDE EFFECT; VIREMIA; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BOSTON; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955767712     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08821209     Document Type: Article

References (34)

1. Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76-85, 1983 (Pubitemid 13217969)
2. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 116: 488-498, 1992
3. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36-44, 2003 (Pubitemid 36765101)
4. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, Gross WL, Reinhold-Keller E: Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46: 1087-1091, 2007 (Pubitemid 47050609)
5. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puechal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L: Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359: 2790-2803, 2008
6. Bosch X, Guilabert A, Font J: Antineutrophil cytoplasmic antibodies. Lancet 368: 404-418, 2006
7. Golbin JM, Specks U: Targeting B lymphocytes as therapy for ANCA-associated vasculitis. Rheum Dis Clin North Am 33: 741-754, v, 2007
8. Wong CF: Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: What is the current evidence? Nephrol Dial Transplant 22: 32-36, 2007
9. Hinze CH, Colbert RA: B-cell depletion in Wegener's granulomatosis. Clin Rev Allergy Immunol 34: 372-379, 2008
10. Cheson BD, Leonard JP: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359: 613-626, 2008
11. Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, Dougados M, Ferraccioli G, Jaeger U, Klareskog L, Kvien TK, Martin-Mola E, Pavelka K: Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66: 143-150, 2007
12. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L: Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: A study on 8 patients. Clin Exp Rheumatol 25: S23-S27, 2007 (Pubitemid 46656590)
13. Eriksson P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257: 540-548, 2005
14. Keogh KA, Wylam ME, Stone JH, Specks U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262-268, 2005 (Pubitemid 40129256)
15. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U: Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173: 180-187, 2006
16. Roccatello D, Baldovino S, Alpa M, Rossi D, Napoli F, Naretto C, Cavallo R, Giachino O: Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCAassociated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 26: S67-S71, 2008
17. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45: 1432-1436, 2006 (Pubitemid 44605482)
18. Lovric S, Erdbruegger U, Kumpers P, Woywodt A, Koenecke C, Wedemeyer H, Haller H, Haubitz M: Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: A single-centre experience with 15 patients. Nephrol Dial Transplant 24: 179-185, 2009
19. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR: A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60: 2156-2168, 2009
20. Holle JU, Gross WL: ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy. J Autoimmun 32: 163-171, 2009
21. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune JW, St Clair EW, Luqmani RA: A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44: 912-920, 2001
22. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL: Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 126: 866-873, 1997 (Pubitemid 27232627)
23. Fries JF: Advances in management of rheumatic disease. 1965 to 1985. Arch Intern Med 149: 1002-1011, 1989
24. Bosch X, Guilabert A, Espinosa G, Mirapeix E: Treatment of antineutrophil cytoplasmic antibody associated vasculitis: A systematic review. JAMA 298: 655-669, 2007 (Pubitemid 47236417)
25. Turnbull J, Harper L: Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 23: 391-401, 2009
26. Fleischmann RM: Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: Focus on rituximab. Semin Arthritis Rheum 38: 265-280, 2009
27. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E: Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 55: 31-38, 2001 (Pubitemid 32041780)
28. Jayne D: Review article: Progress of treatment in ANCAassociated vasculitis. Nephrology (Carlton) 14: 42-48, 2009
29. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P: The late adverse events of rituximab therapy - Rare but there! Leuk Lymphoma 50: 1083-1095, 2009
30. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL: Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840, 2009
31. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY: Reactivation of hepatitis B virus following rituximab- based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89: 255-262, 2010
32. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH: B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106: 795-802, 2005
33. Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, Fernandez-Pugnaire M, Ortego-Centeno N: Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 157: 1271-1273, 2007 (Pubitemid 350119793)
34. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, Ungari M, Ruggeri G, Rossi G: Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 47: 1013-1017, 2006 (Pubitemid 44102962)